Searched for
ILUMYA APPROVAL
Sun Pharma Q2 profit takes a hit on exceptional itemsSun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue ...- Sun Pharma Q2 profit falls 36% as litigation costs hit earningsSun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Reven...
- Sun Pharma Q2 Results: Profit falls 36% YoY to Rs 1,989 crore on exceptional chargesSun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported...
- MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...
- Sun Pharma’s Ilumya expansion bid gets USFDA nod for reviewSun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for t...
- New launches and R&D pipeline bolster Sun Pharma's long-term growth outlookSun Pharma reported robust global specialty growth and resilient domestic sales in Q3, despite US generics headwinds. Recent product launch...
- Better pill! Jefferies gives a double upgrade to Sun Pharma stockSun Pharma performance has been a mixed bag in the near term as the shares dropped 13 per cent in the last month, whereas rose close to 7 p...
- Sun Pharma bullish on specialty biz, looks to expand the segment to new geographiesSharing information with shareholders, Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company's strategy of develo...
- Sun Pharma arm launches plaque psoriasis treatment drug in JapanIn a regulatory filing, Sun Pharmaceutical Industries said its "wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection...
- Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA regionUnder the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA...
- Sun Pharma ex-employee alleges US Law violation, discriminationSandra Hagenbrock, who was national account director at Sun in the US and employed there from February 2016 to July 2019, alleged the compa...
- Sun Pharma posts Q2 profit of Rs 1,064 crore, meets Street estimatesThe drug maker had reported a loss of Rs 269.60 crore in the corresponding quarter last year.
- Sun Pharma's Q1 nos: One-off boost likely from US suppliesCentrum Broking expects Sun Pharma's India sales to grow at 7 per cent for the quarter.
- Buy Sun Pharmaceutical Industries, target Rs 581: Nirmal Bang Institutional EquitiesBuy Sun Pharmaceutical Industries at a price target of Rs 581.
- Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Sun Pharma climbs over 3% after USFDA drug nodThe company informed stock exchanges about the USFDA nod after market hours of Wednesday.
- Sensex gains over 50 pts, Nifty nears 10,200; India VIX eases 3%Equity market opened on a positive note after US Fed hiked interest rate by 25 bps.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Sun Pharma gets USFDA nod for plaque psoriasis drugThe FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.
Load More
